Asian perspectives on the recognition and management of levodopa 'wearing-off' in Parkinson's disease.

Roongroj Bhidayasiri,Nobutaka Hattori,Beomseok Jeon,Rou-Shayn Chen,Moon Keen Lee,Jawad A Bajwa,Vincent C T Mok,Baorong Zhang,Thamrin Syamsudin,Louis Chew Seng Tan,Roland Dominic G Jamora,Apichart Pisarnpong,Werner Poewe

DOI: https://doi.org/10.1586/14737175.2015.1088783

IF: 4.287

2015-01-01

Expert Review of Neurotherapeutics

Abstract:Most Parkinson's disease patients will receive levodopa therapy, and of these, the majority will develop some levodopa-induced complications. For many patients, the first complication to develop is the decline in the duration of therapeutic benefit of each levodopa dose, a phenomenon commonly termed 'wearing-off'. There is already extensive literature documenting the epidemiology and management of wearing-off in Parkinson's disease patients of western descent. However, data derived from these studies might not always apply to patients of Asian descent due to genetic variations, differences in co-morbidities or non-availability of certain drugs. This review summarizes the current literature regarding the epidemiology of wearing-off in Asian (including Arab) patients and discusses the management issues in the context of drug availability in Asia.